These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 28401443)

  • 1. Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab.
    Brilli L; Danielli R; Ciuoli C; Calabrò L; Di Giacomo AM; Cerase A; Paffetti P; Sestini F; Porcelli B; Maio M; Pacini F
    Endocrine; 2017 Dec; 58(3):535-541. PubMed ID: 28401443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting development of ipilimumab-induced hypophysitis: utility of T4 and TSH index but not TSH.
    Siddiqui MS; Lai ZM; Spain L; Greener V; Turajlic S; Larkin J; Morganstein DL
    J Endocrinol Invest; 2021 Jan; 44(1):195-203. PubMed ID: 32449093
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody.
    Iwama S; De Remigis A; Callahan MK; Slovin SF; Wolchok JD; Caturegli P
    Sci Transl Med; 2014 Apr; 6(230):230ra45. PubMed ID: 24695685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fall in thyroid stimulating hormone (TSH) may be an early marker of ipilimumab-induced hypophysitis.
    De Sousa SMC; Sheriff N; Tran CH; Menzies AM; Tsang VHM; Long GV; Tonks KTT
    Pituitary; 2018 Jun; 21(3):274-282. PubMed ID: 29380110
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma.
    Albarel F; Gaudy C; Castinetti F; Carré T; Morange I; Conte-Devolx B; Grob JJ; Brue T
    Eur J Endocrinol; 2015 Feb; 172(2):195-204. PubMed ID: 25416723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pituitary enlargement following ipilimumab without long term endocrine dysfunction.
    Nogueira E; Menon A; Dede A; Mitra I; Brock C; Larkin J; Morganstein D
    Curr Probl Cancer; 2021 Dec; 45(6):100710. PubMed ID: 33622518
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.
    Ryder M; Callahan M; Postow MA; Wolchok J; Fagin JA
    Endocr Relat Cancer; 2014 Apr; 21(2):371-81. PubMed ID: 24610577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma.
    Kassi E; Angelousi A; Asonitis N; Diamantopoulos P; Anastasopoulou A; Papaxoinis G; Kokkinos M; Giovanopoulos I; Kyriakakis G; Petychaki F; Savelli A; Benopoulou O; Gogas H
    Cancer Med; 2019 Nov; 8(15):6585-6594. PubMed ID: 31518074
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ipilimumab-induced hypophysitis, a single academic center experience.
    Snyders T; Chakos D; Swami U; Latour E; Chen Y; Fleseriu M; Milhem M; Zakharia Y; Zahr R
    Pituitary; 2019 Oct; 22(5):488-496. PubMed ID: 31327112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study.
    Min L; Hodi FS; Giobbie-Hurder A; Ott PA; Luke JJ; Donahue H; Davis M; Carroll RS; Kaiser UB
    Clin Cancer Res; 2015 Feb; 21(4):749-55. PubMed ID: 25538262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ipilimumab Induced Hypophysitis: MRI Findings in a Series of 3 Cases.
    Wadhwa V
    J Ark Med Soc; 2017 May; 113(11):270-272. PubMed ID: 30351740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma.
    Faje AT; Sullivan R; Lawrence D; Tritos NA; Fadden R; Klibanski A; Nachtigall L
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4078-85. PubMed ID: 25078147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ipilimumab-Induced Autoimmune Hypophysitis: Diagnostic and Management Challenges Illustrated by a Clinical Case.
    Marques P; Grossman A
    Acta Med Port; 2015; 28(6):775-9. PubMed ID: 27265913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterisation of the onset and severity of adrenal and thyroid dysfunction associated with CTLA4-related hypophysitis.
    Seejore K; Giannoudi M; Osborn D; Lynch JM; Al-Qaissi A; Dunwoodie E; Hook J; Marples M; Murray RD
    Eur J Endocrinol; 2021 Dec; 186(1):83-93. PubMed ID: 34735371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nivolumab-induced hypophysitis in a patient with advanced malignant melanoma.
    Okano Y; Satoh T; Horiguchi K; Toyoda M; Osaki A; Matsumoto S; Tomaru T; Nakajima Y; Ishii S; Ozawa A; Shibusawa N; Shimada T; Higuchi T; Chikamatsu K; Yamada M
    Endocr J; 2016 Oct; 63(10):905-912. PubMed ID: 27440480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose glucocorticoids for the treatment of ipilimumab-induced hypophysitis is associated with reduced survival in patients with melanoma.
    Faje AT; Lawrence D; Flaherty K; Freedman C; Fadden R; Rubin K; Cohen J; Sullivan RJ
    Cancer; 2018 Sep; 124(18):3706-3714. PubMed ID: 29975414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ipilimumab, not just another anti-cancer therapy: hypophysitis as side effect illustrated by four case-reports.
    Marlier J; Cocquyt V; Brochez L; Van Belle S; Kruse V
    Endocrine; 2014 Dec; 47(3):878-83. PubMed ID: 24554495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ipilimumab-induced hypophysitis in melanoma patients: an Australian case series.
    Lam T; Chan MM; Sweeting AN; De Sousa SM; Clements A; Carlino MS; Long GV; Tonks K; Chua E; Kefford RF; Chipps DR
    Intern Med J; 2015 Oct; 45(10):1066-73. PubMed ID: 26010858
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ipilimumab-induced hypophysitis and uveitis in a patient with metastatic melanoma and a history of ipilimumab-induced skin rash.
    Nallapaneni NN; Mourya R; Bhatt VR; Malhotra S; Ganti AK; Tendulkar KK
    J Natl Compr Canc Netw; 2014 Aug; 12(8):1077-81. PubMed ID: 25099440
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.